Semax
ACTH-fragment analogue
Semax is an ACTH-fragment analogue investigated in neurological research. This entry concentrates on a primary rat study of neurotrophin gene expression and its limits.
Reviewed September 2026
- Residues
- 7. calculated: Count of residues in the stored canonical reference sequence; terminal groups are not extra residues.
- Average mass
- 813.92 Da. calculated: Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded.
- pI
- 5.22 (theoretical). calculated: Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation.
Calculated properties
| Formula | C37H51N9O10S |
|---|---|
| Monoisotopic mass | 813.3480 Da |
| Extinction coefficient at 280 nm | None (no Tyr or Trp) |
| A280 at 1 mg/mL | Not measurable |
| Residues | 7 |
| Average mass | 813.92 Da |
| pI | 5.22 (theoretical) |
| Aliases | ACTH-fragment analogue |
|---|---|
| Sequence | MEHFPGP |
| Research area | Neurological |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Calculation scope: the stored canonical amino-acid sequence with free N- and C-termini, no other modifications or counterions. This specifies a reference form, not the chemical form or identity of a sold lot.
- Residues: 7 (calculated). Count of residues in the stored canonical reference sequence; terminal groups are not extra residues. Residues source 1
- Average mass: 813.92 Da (calculated). Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded. Average mass source 1 Average mass source 2 Average mass source 3
- pI: 5.22 (theoretical) (calculated). Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation. pI source 1 pI source 2
Residue composition
- Unique residues
- 6
- Most common
- Proline
- Nonpolar residues
- 0
- Other classified residues
- 7
Proline is the most common residue (2). The calculated charge at pH 7 is net negative (-0.92).
Reference scope and linked records
Reference type: Peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Semax. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Neurotrophin gene expression in rat brain under the action of Semax. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Semax
Identity and context
The peptide is described by the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is not full-length ACTH and should not be treated as chemically identical to Selank or to products described only as modified Semax analogues.
Reference classification
Peptide. The linked catalogue product is Semax. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm the exact peptide and any terminal modification. Keep unmodified Semax, acetylated derivatives and incompletely specified analogue names separate in the experiment and source record.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | A primary study measured rapid changes in NGF and BDNF gene expression across regions of normal rat brain. The response varied by gene and brain region, including increases in some regions and a decrease in frontal-cortex NGF expression. A single slogan such as increases BDNF would leave out important experimental context. | Source context |
| What cannot be inferred | These measurements are not proof of cognitive enhancement or recovery from a neurological condition in humans. They also do not identify Adamax or demonstrate the behaviour of a purported Semax derivative. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Neurotrophin gene expression in rat brain under the action of SemaxPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.